Zynerba Pharmaceuticals Inc. (ZYNE) Trading Down 0.8%
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)’s share price was down 0.8% on Friday . The stock traded as low as $7.16 and last traded at $7.36, with a volume of 101,558 shares changing hands. The stock had previously closed at $7.30.
Several equities analysts have recently weighed in on ZYNE shares. Oppenheimer Holdings Inc. restated a “buy” rating and issued a $29.00 price objective on shares of Zynerba Pharmaceuticals in a report on Monday, May 16th. Canaccord Genuity reiterated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, April 18th. Jefferies Group reiterated a “buy” rating and set a $32.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, April 7th. Roth Capital began coverage on Zynerba Pharmaceuticals in a report on Thursday, March 17th. They set a “buy” rating and a $25.00 price target for the company. Finally, Zacks Investment Research cut Zynerba Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 18th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has an average rating of “Buy” and an average price target of $32.60.
The firm’s market capitalization is $67.70 million. The company has a 50-day moving average price of $7.90 and a 200-day moving average price of $8.31.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Thursday, May 12th. The company reported ($0.49) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.07. On average, equities analysts forecast that Zynerba Pharmaceuticals Inc. will post ($2.37) EPS for the current fiscal year.
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.